{"id":"NCT02395133","sponsor":"Regeneron Pharmaceuticals","briefTitle":"A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-25","primaryCompletion":"2016-07","completion":"2016-10-18","firstPosted":"2015-03-20","resultsPosted":"2018-10-17","lastUpdate":"2020-03-11"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["REGN668","SAR231893"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab 300 mg Q8W","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg Q4W","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg Q2W/QW","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.","primaryOutcome":{"measure":"Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)","timeFrame":"Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)","effectByArm":[{"arm":"Placebo QW","deltaMin":21.67,"sd":3.134},{"arm":"Dupilumab 300 mg Q8W","deltaMin":6.84,"sd":2.434},{"arm":"Dupilumab 300 mg Q4W","deltaMin":3.84,"sd":2.283},{"arm":"Dupilumab 300 mg Q2W/QW","deltaMin":0.06,"sd":1.736}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["39969783","39588375","31876900"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":82},"commonTop":["Dermatitis atopic","Nasopharyngitis","Upper respiratory tract infection","Headache","Injection site reaction"]}}